Deere's Repair Settlement Clears the Last Overhang on a Cycle Bottom

The right-to-repair dispute has been an under-priced tail risk on Deere's equity story for two reasons. First, the regulatory arc: if state-level right-to-repair legislation had expanded to cover diagnostic software in all jurisdictions, the precision agriculture business (which depends heavily on proprietary software interfaces) would have faced a structural margin compression of 200-400 basis points. Second, the reputational arc: the dispute had become a narrative anchor for every bearish view on the stock, colouring sell-side models and investor positioning.

With the settlement in place, both arcs close. The regulatory arc resolves because the settlement establishes a framework that preempts further legislative action. The reputational arc resolves because the case universe is largely cleared and the headline risk is behind the company.

This pattern of 'last overhang clears at cycle trough' has historically been an excellent long entry for industrial cyclicals. The 2017 Emerson right-to-repair settlement analogue preceded a 35% re-rate over the following 18 months. The 2015 Union Pacific regulatory clearance preceded a similar re-rate. The pattern is not a guarantee, but the probability weight is meaningful.

The Capital Desk reads the timing as the opposite of unfortunate. Settling at the cycle trough, when management attention can focus on the recovery leg rather than on legal defence, is the kind of capital allocation that should inform the current valuation. The overhang has been absorbed; the recovery is ahead.

Deere's capital allocation discipline through cycles is what makes the name investable at a relatively high trough multiple. Across the FY2021-FY2025 window, the company returned approximately $35 billion to shareholders through dividends ($4 billion) and buybacks ($31 billion). The buyback pace was deliberately elevated during the FY2024-FY2025 cycle pullback, when the share price was compressed by 20-30% from peak.

The math of through-cycle buybacks is where Deere's capital allocation edge lives. Share count fell from 313 million in FY2021 to 275 million in FY2025, a 12% compression. Buyback execution has been weighted to the lower end of the price range within each fiscal year, which is exactly the disciplined pattern that creates per-share value. Every $1 billion of buyback at today's $580 price removes approximately 1.1% of shares outstanding. At the cycle recovery top, assuming mid-cycle EPS of $22-24, the per-share value of today's buybacks compounds into the recovery leg.

The balance sheet supports continuation. Cash stood at $8.3 billion at fiscal year-end 2025, against total debt that includes the captive finance operation. Strip out the financial services segment (which is run to asset-liability match targets) and the industrial balance sheet carries net debt to EBITDA of 0.8x. That is plenty of flexibility to maintain the buyback pace through any further cycle softness.

The dividend yield of 1.11% is modest but is also growing; the five-year dividend CAGR is 10%. The total capital return to shareholders, counting buybacks, runs at approximately 5-6% of market cap annually through the cycle. That is a substantial carry floor while the recovery leg develops.

Return on invested capital through the cycle has averaged approximately 15% against a weighted-average cost of capital of roughly 8%. The 700 basis point spread is the economic engine that makes the buyback math creative. As long as ROIC remains above WACC through the recovery, the buyback compounds per-share value whether or not the cycle delivers as expected.

Historically, the ag equipment cycle runs on roughly a 7-10 year arc from trough to trough. The 2013-2016 down-leg compressed Deere's revenue by 28% over three years. The 2008 down-leg compressed revenue by 19% in a single year. The current FY2023-FY2025 compression of 26% sits closer to the 2013-2016 analogue in both magnitude and duration.

In each of the prior two cycles, the recovery leg began with inventory destocking bottoming, new-equipment order rates stabilising, and farm income expectations turning. The data on each of those three indicators in early 2026 points to a cycle that is approximately 6-9 months past the trough on orders and approximately 3-6 months past the trough on inventory. That sets up a revenue acceleration from FY2026 into FY2027-FY2028, albeit at a moderate rather than aggressive slope.

One data point the Capital Desk watches carefully is US grain prices. The 2013-2016 cycle bottom coincided with corn prices stabilising in the $3-4 range; the recovery leg was accompanied by a move to the $4-5 range. Corn prices today sit in the $4.20-4.50 range, already somewhat elevated from the trough. That implies the revenue recovery into FY2027 could be steeper than the 2013-2016 parallel because the commodity signal is already partially in place.

Historically, when ag cycles bottom with commodity prices supportive and a major legal overhang clearing, the 24-month forward return has been positive in four of the last four analogous set-ups. The probability weight on the current trade is not a coin flip; it is a favourable base rate.

The competitive dynamics inside the ag equipment sector have reshuffled modestly during the current down-leg. AGCO has executed aggressively on precision-ag partnerships, adding roughly 200 basis points of segment share in North American row-crop applications. CNH has been more cautious and has lost approximately 100 basis points of share. Kubota has continued its strategy of expanding into compact and sub-compact categories where Deere's presence is smaller. On aggregate, Deere has held approximately 48% share of large agricultural equipment in North America through the cycle, within 100 basis points of its historical norm.

The more interesting competitive read is on precision agriculture, where Deere's moat is based on the integration of hardware, software and data. AGCO's partnership strategy requires third-party integration, which limits margin capture. Deere's proprietary stack carries a gross margin premium of 400-500 basis points over hardware-only segments. The repair settlement does not meaningfully erode that premium because the framework preserves the proprietary software interface; it expands third-party diagnostic access within defined bounds rather than open-sourcing the platform.

The competitive moat is therefore intact through the settlement. That is the single most important point for understanding why the stock has held its multiple through the cycle trough. If the moat had broken on the settlement, the forward multiple should compress to the low-20s. It has not. The market is correctly pricing a preserved moat, and the cycle-recovery leg is the additional optionality on top.

Three drivers shape the recovery leg. First, replacement demand. The installed base of large agricultural equipment across North America is at its oldest average age in twenty years. Farmers have deferred replacement through the down-leg, creating a demand backlog that will release as commodity prices support farm income. Estimates of the replacement-driven revenue contribution through FY2028 run at $8-12 billion, spread across the 36-month recovery window.

Second, precision-ag uptake. See-and-Spray and autonomous guidance systems have penetration rates of 15-25% in core row-crop applications, against a theoretical ceiling of 60-70%. Every 5 percentage points of penetration uptake adds approximately $500 million of incremental revenue at above-corporate-average margins. The settlement does not meaningfully slow this uptake curve.

Third, international growth. Latin American markets (Brazil, Argentina) have continued to grow through the North American trough. South American revenue in FY2025 was $6.2 billion against $5.4 billion in FY2023. The geographic diversification has a stabilising effect on the consolidated cycle, reducing amplitude modestly relative to a pure North American book.

Stack those three drivers across the FY2026-FY2028 recovery window and the mid-cycle revenue walk points to $55-58 billion annually, with operating income of $12-13 billion. The normalised EPS base is $22-25. At the current multiple, that implies a fair value of $700-750 on mid-cycle earnings.

The 50-day moving average sits at $595, above the 200-day at $513. The spread between the two is widening, with the 200-day slope turning positive in Q1 2026. The 52-week range of $430 to $672 captures the full cycle compression and the early-stage recovery. Beta of 0.99 reflects the cyclical nature of the book.

The stock has retraced approximately 50% of its FY2023 cycle-peak decline as of mid-April 2026. In prior cycles, that retracement level has typically been followed by either a consolidation phase (which is broadly what the technicals suggest for the near term) or a slower grind toward the prior cycle highs. A sharp breakout from current levels would require either an earlier-than-expected cycle acceleration or a major capital allocation event (a meaningful accelerated buyback program, for example).

The implied volatility environment has compressed from the FY2024 highs. That compression historically correlates with institutional positioning rather than retail speculation, consistent with a cycle-bottom accumulation pattern. The 13F data through early 2026 confirms net institutional buying across the top 30 long-only industrial investors over the last two quarters.